1.
Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381-1387. doi:10.1038/s41588-018-0204-y.
1.
Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690-705.e9. doi:10.1016/j.ccell.2018.03.014.
1.
Cuomo CA, Birren BW. The fungal genome initiative and lessons learned from genome sequencing. Methods Enzymol. 2010;470:833-55. doi:10.1016/S0076-6879(10)70034-3.
1.
Balasubramanian S, Fu Y, Pawashe M, et al. Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes. Nat Commun. 2017;8(1):382. doi:10.1038/s41467-017-00443-5.
1.
Emdin CA, Khera AV, Chaffin M, et al. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nat Commun. 2018;9(1):1613. doi:10.1038/s41467-018-03911-8.
1.
Whiffin N, Minikel E, Walsh R, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017;19(10):1151-1158. doi:10.1038/gim.2017.26.
1.
Udler MS, Kim J, von Grotthuss M, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med. 2018;15(9):e1002654. doi:10.1371/journal.pmed.1002654.
1.
Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematol. 2018;5(6):e241-e251. doi:10.1016/S2352-3026(18)30053-X.
1.
Zhang Y, Ng PK-S, Kucherlapati M, et al. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017;31(6):820-832.e3. doi:10.1016/j.ccell.2017.04.013.
1.
Ganna A, Satterstrom K, Zekavat SM, et al. Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet. 2018;102(6):1204-1211. doi:10.1016/j.ajhg.2018.05.002.